ORIC Pharmaceuticals (ORIC) Competitors $7.64 -0.39 (-4.86%) Closing price 04:00 PM EasternExtended Trading$7.78 +0.14 (+1.79%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ORIC vs. PTGX, CNTA, MESO, CGON, AGIO, HRMY, IDYA, BLTE, JANX, and GLPGShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Protagonist Therapeutics (PTGX), Centessa Pharmaceuticals (CNTA), Mesoblast (MESO), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Janux Therapeutics (JANX), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. Protagonist Therapeutics Centessa Pharmaceuticals Mesoblast CG Oncology Agios Pharmaceuticals Harmony Biosciences IDEAYA Biosciences Belite Bio Janux Therapeutics Galapagos Protagonist Therapeutics (NASDAQ:PTGX) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Does the MarketBeat Community believe in PTGX or ORIC? Protagonist Therapeutics received 212 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 74.74% of users gave ORIC Pharmaceuticals an outperform vote while only 61.12% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformProtagonist TherapeuticsOutperform Votes28361.12% Underperform Votes18038.88% ORIC PharmaceuticalsOutperform Votes7174.74% Underperform Votes2425.26% Do analysts recommend PTGX or ORIC? Protagonist Therapeutics currently has a consensus target price of $55.44, suggesting a potential upside of 47.50%. ORIC Pharmaceuticals has a consensus target price of $18.86, suggesting a potential upside of 134.83%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in PTGX or ORIC? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to PTGX or ORIC? In the previous week, ORIC Pharmaceuticals had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 18 mentions for ORIC Pharmaceuticals and 17 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.68 beat ORIC Pharmaceuticals' score of 0.53 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive ORIC Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PTGX or ORIC more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to ORIC Pharmaceuticals' net margin of 0.00%. Protagonist Therapeutics' return on equity of 34.68% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics52.76% 34.68% 30.98% ORIC Pharmaceuticals N/A -44.54%-40.72% Which has more risk & volatility, PTGX or ORIC? Protagonist Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Which has higher valuation and earnings, PTGX or ORIC? Protagonist Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M5.31-$78.96M$4.208.95ORIC PharmaceuticalsN/AN/A-$100.70M-$1.82-4.41 SummaryProtagonist Therapeutics beats ORIC Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$570.35M$7.20B$5.83B$8.61BDividend YieldN/A2.79%4.75%3.97%P/E Ratio-4.416.2825.1919.55Price / SalesN/A204.40384.30115.49Price / CashN/A65.6738.0534.58Price / Book2.356.607.564.43Net Income-$100.70M$139.24M$3.19B$247.27M7 Day Performance6.22%-1.44%-1.83%-2.06%1 Month Performance-20.89%-4.76%-3.55%-3.75%1 Year Performance-45.23%-11.97%14.04%6.40% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals4.3444 of 5 stars$7.64-4.9%$18.86+146.8%-45.2%$542.65MN/A-4.2080Analyst RevisionPTGXProtagonist Therapeutics3.7472 of 5 stars$36.00-7.1%$55.44+54.0%+16.9%$2.15B$323.80M13.53120Analyst ForecastNews CoverageGap UpCNTACentessa Pharmaceuticals2.272 of 5 stars$15.66-5.8%$25.83+65.0%+43.1%$2.06B$6.85M-10.24200Short Interest ↑MESOMesoblast1.5531 of 5 stars$16.23-0.9%$18.00+10.9%+740.7%$2.06B$5.90M0.0080News CoverageGap DownCGONCG Oncology1.3596 of 5 stars$26.78-3.8%$65.14+143.3%-41.2%$2.04B$200,000.000.0061AGIOAgios Pharmaceuticals4.4403 of 5 stars$35.47+0.7%$56.57+59.5%+10.1%$2.03B$36.50M3.13390HRMYHarmony Biosciences4.6157 of 5 stars$34.18-1.1%$53.67+57.0%+5.4%$1.95B$582.02M16.20200Earnings ReportAnalyst RevisionIDYAIDEAYA Biosciences4.1007 of 5 stars$21.31-2.5%$53.58+151.4%-55.5%$1.87B$7M-6.4680Gap UpBLTEBelite Bio2.5576 of 5 stars$56.52-0.8%$96.33+70.4%+23.0%$1.80BN/A-50.9210Upcoming EarningsJANXJanux Therapeutics3.4008 of 5 stars$33.58-6.7%$89.90+167.7%-31.0%$1.76B$13.05M-28.7030Earnings ReportAnalyst ForecastGLPGGalapagos0.2509 of 5 stars$26.56-0.7%$26.75+0.7%-25.7%$1.75B$275.65M0.001,123Gap Up Related Companies and Tools Related Companies Protagonist Therapeutics Competitors Centessa Pharmaceuticals Competitors Mesoblast Competitors CG Oncology Competitors Agios Pharmaceuticals Competitors Harmony Biosciences Competitors IDEAYA Biosciences Competitors Belite Bio Competitors Janux Therapeutics Competitors Galapagos Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORIC) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORIC Stock Alerts